| Schedule of notes payable |
| |
|
June
30, 2016 |
|
|
December
31, 2015 |
|
| Loan payable under prepaid forward purchase contract |
|
$ |
5,000,000 |
|
|
$ |
– |
|
| |
|
|
|
|
|
|
|
|
| Loan payable to TCA Global Master Fund, LP in the principal amount
of $3,000,000 at 16% interest, with interest only payments through September 11, 2016 (the "TCA Debenture"). Principal
and interest payments due monthly from October 11, 2016 through September 11, 2017. |
|
|
3,000,000 |
|
|
|
3,000,000 |
|
| |
|
|
|
|
|
|
|
|
| Note payable to CommerceNet in the original principal
amount of $250,000, bearing interest at 6% per annum. Principal and interest payments are made annually from July 12, 2015
through July 12, 2017 |
|
|
170,806 |
|
|
|
170,806 |
|
| |
|
|
|
|
|
|
|
|
| Note payable to Jay Tenenbaum in the original principal amount of
$250,000, bearing interest at 6% per annum. Principal and interest payments are made annually from July 12, 2015 through July
12, 2017 |
|
|
170,806 |
|
|
|
170,806 |
|
| |
|
|
|
|
|
|
|
|
| Loan payable to former shareholder of Epinex Diagnostics Laboratories,
Inc. in the original principal amount of $400,000, at 0% interest, with principal payments due in periodic installments of
$100,000 from November 26, 2014 through February 26, 2016 (the "Epinex Note") |
|
|
– |
|
|
|
100,000 |
|
| |
|
|
|
|
|
|
|
|
| Unamortized discount on TCA Note |
|
|
(305,188 |
) |
|
|
(453,025 |
) |
| Unamortized discount on Epinex Note |
|
|
– |
|
|
|
(1,775 |
) |
| Derivative liability associated with the TCA
Note, at fair value |
|
|
420,333 |
|
|
|
186,117 |
|
| |
|
|
8,456,757 |
|
|
|
3,172,929 |
|
| Less current portion |
|
|
(7,546,335 |
) |
|
|
(269,031 |
) |
| Note payable - third parties,
net of current portion |
|
|
910,422 |
|
|
|
2,903,898 |
|
|
| Schedule of notes payable - related parties |
| |
|
June
30, 2016 |
|
|
December
31, 2015 |
|
| Convertible debenture dated December 31, 2014 which
bears interest at 10% per annum and is due December 31, 2016 (the "D&D Debenture"). The note provides the lender, D&D
Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price
(as defined in the note agreement) for ten consecutive trading days prior to the conversion date |
|
$ |
750,000 |
|
|
$ |
3,000,000 |
|
| |
|
|
|
|
|
|
|
|
| Loan payable to Alcimede, LLC, bearing interest at 6% per annum,
with all principal and interest due on February 2, 2017 |
|
|
500,000 |
|
|
|
500,000 |
|
| |
|
|
|
|
|
|
|
|
| Loan payable to Christopher Diamantis |
|
|
2,700,000 |
|
|
|
1,600,000 |
|
| |
|
|
|
|
|
|
|
|
| Loan payable to Thomas Mendolia |
|
|
400,000 |
|
|
|
– |
|
| |
|
|
|
|
|
|
|
|
| Unamortized discount on D&D Debenture |
|
|
(297,843 |
) |
|
|
(2,236,112 |
) |
| Derivative liabilities associated with the
D&D Debenture, at fair value |
|
|
1,060,833 |
|
|
|
2,270,000 |
|
| Current portion of notes
payable, related parties |
|
|
5,112,990 |
|
|
|
5,133,888 |
|
|